Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women

Current Medical Research and Opinion

Volumn 24, Issue 11, 2008, Pages 3259-3274

  Adami, Silvano ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Bone mineral density; Osteoporosis; Parathyroid hormone; PTH(1 84); Vertebral fracture

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; ESTROGEN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

BONE DENSITY; BONE METABOLISM; CELL METABOLISM; CLINICAL FEATURE; CLINICAL TRIAL; CORTICAL BONE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GROUPS BY AGE; HIP; HUMAN; INCIDENCE; LOW DRUG DOSE; LUMBAR SPINE; MONOTHERAPY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; TRABECULAR BONE; TREATMENT DURATION; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; FEMALE; HUMANS; MODELS, BIOLOGICAL; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 67649392449     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802518130     Document Type: Review

References (124)

1. Heaney RP. Osteoporosis 2044. Osteoporosis Int 1994;4:233-237
2. Magaziner J, Lydick E, Hawkes W, et al. Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health 1997;87:1630-1636 (Pubitemid 27465238)
3. Dreinhöfer KE, Féron JM, Herrera A, et al. Orthopaedic surgeons and fragility fractures. A survey by the Bone and Joint Decade and the International Osteoporosis foundation. J Bone Joint Surg 2004;86:958-961
4. Lippuner K, von Overbeck J, Perrelet R, et al. Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland. Osteoporosis Int 1997;7:414-425 (Pubitemid 27443066)
5. Chapurlat RD, Bauer DC, Nevitt M, et al. Incidence and risk factors for a second hip fracture in elderly women. The study of osteoporotic fractures. Osteoporosis Int 2003;14:130-136
6. Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporosis Int 2004;15:38-42 (Pubitemid 38252438)
7. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-323 (Pubitemid 32095035)
8. Adachi JD, Ioannidis G, Olszynski WP, et al. The impact of incident vertebral and nonvertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskel Dis 2002;3:11 (Pubitemid 38994415)
9. Hall SE, Criddle RA, Comito TL, et al. A case-control study of quality of life and functional impairment in women with longstanding vertebral osteoporotic fracture. Osteoporosis Int 1999;9:508-515 (Pubitemid 29348566)
10. Gold DT. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 1996;18:185S-9 (Pubitemid 126352529)
11. Melton JL, Atkinson EJ, O'Connor MK, et al. Bone density and fracture risk in men. J Bone Miner Res 1998;13:1915-1923 (Pubitemid 28535849)
12. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103:12-17 (Pubitemid 27386437)
13. Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-2018
14. Ebeling PR, Atley LM, Guthrie JR, et al. Bone turnover markers and bone density across the menopausal transition. J Clin Endocr Metab 1996;81:3366-3371 (Pubitemid 26296217)
15. Parfitt AM, Villanueva AR, Foldes J, et al. Relations between histologic indices of bone formation: implications for the pathogenesis of spinal osteoporosis. J Bone Miner Res 1995;10:466-473
16. Baldock PA, Eisman JA. Genetic determinants of bone mass. Curr Opin Rheumatol 2004;16:450-456 (Pubitemid 38803148)
17. Ioannidis JPA, Ralston SH, Bennett ST, et al. Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA 2004;292:2105-2114 (Pubitemid 39435101)
18. Liu YZ, Liu YJ, Recker R, et al. Molecular studies of identification of genes for osteoporosis: the 2002 update. J Endocrinol 2003;177:147-196
19. Lips P. Which circulating level of 25 hydroxy vitamin D is appropriate? J Steroid Biochem Mol Biol 2004;89:611-614
20. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115:3318-3325 (Pubitemid 43121814)
21. Boonen S, Bischoff-Ferrari HA, Cooper C, et al. Addressing the musculoskeletal. components of fracture risk with calcium and vitamin D: A review of the evidence. Calcified Tissue Int 2006;78:257-270 (Pubitemid 43725188)
22. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006 (Pubitemid 38544282)
23. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic interventions. Endocr Rev 2001;22:477-501 (Pubitemid 32762324)
24. Freedman KB, Kaplan FS, Bilker WB, et al. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 2000;82:1063-1070
25. Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002;162:2217-2222 (Pubitemid 35231591)
26. Port L, Center J, Briffa NK, et al. Osteoporotic fracture: missed opportunity for intervention. Osteoporosis Int 2003;14:780-784 (Pubitemid 37295842)
27. Gehlbach SH, Fournier M, Bigelow C. Recognition of osteoporosis by primary care physicians. Am J Public Health 2002;92:271-273 (Pubitemid 34101440)
28. Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporosis Int 2003;14:2-12 (Pubitemid 36267895)
29. Panneman MJ, Lips P, Sen SS, et al. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporosis Int 2004;15:1201-1224 (Pubitemid 38252425)
30. Matsumoto T, Shiraki M, Hagino H, et al. Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study. Osteoporosis Int 2006;17:1532-1538
31. Hodsman AB, Steer BM, Fraher LJ, et al. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner 1991;14:67-83
32. Reeve J TJ, Parsons JA. Preliminary trial of low doses of parathyroid hormone 1-34 peptide in treatment of osteoporosis. Clin Endocrinol (Oxf) 1976;21:469-477
33. Stewart AF. PTHrP (1-36) as a skeletal. anabolic agent for the treatment of osteoporosis. Bone 1996;19:303-306
34. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001;344:1434-1441
35. Dobnig H. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis. Expert Opin Pharmacother 2004;5:1153-1162 (Pubitemid 38702343)
36. Quattrochi E, Kourlas H. Teriparatide: a review. Clin Ther 2004;26:841-854 (Pubitemid 38943033)
37. Tashjian AH Jr, Gagel RF. Teriparatide: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006;21:354-365 (Pubitemid 43306556)
38. Brewer HB, Ronan R. Bovine parathyroid hormone: amino acid sequence. Proc Natl Acad Sci USA 1970;67:1862-1869
39. Niall HD, Keutmann H, Sauer R, et al. The amino acid sequence of bovine parathyroid hormone I. Hoppe-Seylers Zeitschrift fur Physiologische Chemie 1970;351:1586-1588
40. Nguyen-Yamamoto L, Rousseau L, Brossard J-H, et al. Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays. Eur J Endocrinol 2002;147:123-131 (Pubitemid 34814749)
41. Jüppner H, Abou-Samra AB, Freeman M, et al. A G protein linked receptor for parathyroid hormone and parathyroid hormone related peptide. Science 1991;254:1024-1026 (Pubitemid 21917436)
42. Abou-Samra AB, Juppner H, Force T, et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium. Proc Natl Acad Sci USA 1992;89:2732-2736
43. Collip JB. The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calcium. J Biol Chem 1925;63:395-438
44. Selye H. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology 1932;16:547
45. Murray TM, Rao LG, Divieti P, et al. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl- terminal region and related biological actions of carboxylterminal ligands. Endocrine Rev 2005;26:78-113 (Pubitemid 40209388)
46. Potts JT. Parathyroid hormone: past and present. J Endocrinol 2005;187:311-325 (Pubitemid 43020252)
47. Rixon RH, Whitfield JF, Youdale R. Increased survival of rats irradiated with x-rays and treated with parathyroid extract. Nature 1958;182:1374
48. Rixon RH, Whitfield JF. Parathyroid hormone: a possible initiator of liver regeneration. Proc Soc Exp Biol Med 1972;141:93-97
49. Whitfield JF, Perris AD, Youdale T. The calcium-mediated promotion of mitotic activity in rat thymocyte populations by growth hormone, neurohormones, parathyroid hormone and prolactin. J Cell Physiol 1969;73:203-211
50. Khosla S. The OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5055
51. Garabedian M, Holick MF, Deluca HF, et al. Control of 25-hydroxycalciferol metabolism by parathyroid glands. Proc Natl Acad Sci USA 1972;69:1673-1676
52. Fraser DR, Kodicek E. Regulation of 25 hydroxycholecalciferol- 1-hydroxylase activity in kidney by parathyroid hormone. Nature New Biology 1973;241:163-166
53. Nemere I, Larsson D. Does PTH have a direct effect on the intestine? J Cell Biochem 2002;86:29-34
54. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703 (Pubitemid 41127277)
55. Jüppner HW, Gardella TJ, Brown EM. Parathyroid hormone and parathyroid hormone-related peptide in the regulation of calcium homeostasis and bone development, 4th edn. Philadelphia: Elsevier, 2000.
56. Bilezikian JP, Brandi ML, Rubin M, et al. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005;257:6-17 (Pubitemid 40129122)
57. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. New Engl J Med 2005;353:555-565
58. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med 2003;349:1207-1215 (Pubitemid 37152030)
59. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326-339
60. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541 (Pubitemid 26411651)
61. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998;280:2077-2082
62. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000;11:83-91 (Pubitemid 30099515)
63. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-1352
64. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of metaanalyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-578 (Pubitemid 34925651)
65. Borah B, Dufresne TE, Ritman EL, et al. Long term risedronate treatment normalises mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 2006;39:345-352 (Pubitemid 43851366)
66. Adami S, Isaia G, Luisetto G, et al. Fracture incidence and characterization in patients on osteoporosis treatment. The ICARO study. J Bone Miner Res 2006;21:1565-1570 (Pubitemid 44484601)
67. Potts JT, Tregear GW, Keutmann HT, et al. Synthesis of a biologically active N terminal tetratriacontapeptide of parathyroid hormone. Proc Natl Acad Sci USA 1971;68:63-67
68. Fraher LJ, Avram R, Watson PH, et al. Comparison of the biochemical responses to human parathyroid hormone (1-31) NH2 and hPTH (1-34) in healthy humans. J Clin Endocrinol Metab 1999;84:2739-2743
69. Whitfield JF. Osteoporosis-treating parathyroid hormone peptides: what are they? What do they do? How might they do it? Curr Opin Investig Drugs 2006;7:349-359
70. Marie PJ. Strontium ranelate: new insights into its dual mode of action. Bone 2007;40:S5-8 (Pubitemid 46562594)
71. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in post-menopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocr Metab 2005;90:2816-3222 (Pubitemid 40686329)
72. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Engl J Med 2004;350:459-468 (Pubitemid 38133766)
73. Blake GM, Fogelman I. Long term effect of strontium ranelate treatment on BMD. J Bone Miner Res 2005;20:1901-1904 (Pubitemid 41532774)
74. Dobnig H TR. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997;138:4607-4612
75. Nijweide PJ, Burger EH, Feyen JHM. Cells of the bone: proliferation, differentiation and hormonal regulation. Physiol Rev 1986;66:855-886 (Pubitemid 17181295)
76. Hattner R, Epker BN, Frost HM. Suggested sequential mode of control of changes in cell behaviour in adult bone remodeling. Nature 1965;206:489-490
77. Adami S, Kanis JA. Assessment of involutional bone loss: methodological and conceptual problems. J Bone Miner Res 1995;10:511-517
78. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in regulation of bone density. Cell 1997;89:309-319 (Pubitemid 27199902)
79. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176 (Pubitemid 28180851)
80. Hsu H, Lacey DL, Dunstan C, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96:3540-3545 (Pubitemid 29168945)
81. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268 (Pubitemid 28213402)
82. Li J, Sarosi I, Yan X-Q, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97:1566-1571 (Pubitemid 30118482)
83. Li J, Morony S, Tan H, et al. Combination of TNF-α and IL-1β induced osteoclast formation and bone formation is dependent on RANK signal transduction. J Bone Miner Res 2001;16(Supp 1):S379
84. Stilgren LS, Rettmer E, Eriksen EF, et al. Skeletal. changes in osteoprotegerin and receptor activator of nuclear factor κB ligand mRNA levels in primary hyperparathyroidism: effects of parathyroidectomy and association with bone metabolism. Bone 2004;35:256-265 (Pubitemid 38789173)
85. Buxton EC, Yao W, Lane NE. Changes in serum receptor activator of nuclear factor-κB ligand, osteoprotegerin and interleukin-6 levels in patients treated with glucocorticoid induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocr Metab 2004;89:3332-3336 (Pubitemid 38951900)
86. Lane NE, Sanchez S, Modin GW. Parathyroid hormone treatment can reverse corticosteroid induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest 1998;102:1627-1633 (Pubitemid 28492231)
87. Dempster DW, Cosman F, Parisien M, et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993;14:690-709 (Pubitemid 24016657)
88. Fox J. Developments in parathyroid hormone and related peptides as bone formation agents. Curr Opin Pharmacol 2002;2:338-344 (Pubitemid 34594378)
89. Mosekilde L, Søgaard CH, Danielsen CC, et al. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH- (1-34) and hPTH-(1-84). Endocrinology 1991;129:421-428
90. Kimmel DB, Bozzato RP, Kronis KA, et al. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 1993;132:1577-1584
91. Fox J, Miller MA, Newman MK, et al. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 2006;79:262-272
92. Qi H, Li M, Wronski TJ. A comparison of the anabolic effects of parathyroid hormone at skeletal. sites with moderate and severe osteopenia in aged ovariectomized rats. J Bone Miner Res 1995;10:949-955
93. Dempster DW, Moreau IA, Varela A, et al. Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months improves trabecular bone architecture: a study of iliac crest biopsies using micro-computed tomography. J Bone Miner Res 2005;20(Supp 1):S98
94. Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocr Metab 2003;88:5212-5220
95. Roux C, Illera-Martín O, Clausen J. Efficacy of PTH (1-84) on vertebral and non-vertebral fractures in postmenopausal women with a high risk of vertebral fractures. Calcified Tissue Int 2007;80(Supp 1):S48
96. Bogado CE, Zanchetta JR, Gordon CL, et al. Treatment of postmenopausal osteoporotic women with parathyroid hormone (1-84) for 18 months decreases BMD but does not affect indices of bone strength at the distal radius. J Bone Miner Res 2006;21(Supp 1):S112
97. Hosking D, Diaz-Curiel M, Rizzoli R, et al. Serum calcium values in postmenopausal women with primary osteoporosis after treatment with full-length parathyroid hormone PTH (1-84). First results from the PEAK study. Calcified Tissue Int 2007;80:S130-1
98. Diaz-Curiel M, Hosking D, Rizzoli R et al. Serum calcium values in postmenopausal women with primary osteoporosis after one month of treatment with PTH(1-84). Abstract no Su- P426 35th European Symposium on Calcified Tissues, Barcelona, Spain, 2008.
99. Greenspan SL, Hanley DA, Morris SA. Bone turnover markers and BMD remain elevated in postmenopausal osteoporotic women through a full 24 months of treatment with human parathyroid hormone 1-84 (PTH). Abstract no F389 28th Annual Meeting of the American Society for Bone and Mineral Research, Philadelphia, USA, 2006.
100. Roux C, Clausen J. Sustained effect of PTH (1-84) on the risk of vertebral fractures 12 months after cessation of therapy. Calcified Tissue Int 2007;80(Supp 1):S146
101. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-1226 (Pubitemid 37152031)
102. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocr Metab 2000;85:2129-2134 (Pubitemid 32269232)
103. Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]. Osteoporosis Int 2004;15:992-997 (Pubitemid 40064654)
104. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-555 (Pubitemid 27348431)
105. Samnegard E, Akhter MP, Recker RR. Maintenance of vertebral body bone mass and strength created by human parathyroid hormone treatment in ovariectomized rats. Bone 2001;28:414-422 (Pubitemid 32385414)
106. Fogelman I, Christiansen C, Spector T. Safety and efficacy of PTH (1-84) at 18 and 24 months in women with postmenopausal osteoporosis receiving hormone therapy: results from the POWER study. J Bone Miner Res 2005;20(Supp 1):S21-2
107. Fogelman I, Fordham JN, Fraser WD, et al. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy. Calcified Tissue Int 2008;83:85-92
108. Fox J, Miller MA, Newman MK, et al. Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone 2007;41:321-330 (Pubitemid 47199143)
109. Zanchetta JR, Bogado CE, Ferretti JL, et al. Effect of teriparatide [recombinant human parathyroid hormone (1-34] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:539-543 (Pubitemid 36241071)
110. Dempster DW, Zhou H, Cosman F, et al. PTH treatment directly stimulates bone formation in cancellous and cortical bone in humans. J Bone Miner Res 2001;16:S179
111. Compston JE. Skeletal. actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 2007;40:1447-1452 (Pubitemid 46756408)
112. Cosman F, Nieves JW, Zion M, et al. Daily versus cyclic parathyroid hormone in women receiving alendronate. New Engl J Med 2005;353:566-575 (Pubitemid 41138938)
113. Hodsman AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocr Metab 1997;82:620-628 (Pubitemid 27068640)
114. NICE Technology Appraisal Guidance. 2005;87
115. Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration and treatment. Toxicol Pathol 2004;32:426-438 (Pubitemid 38998935)
116. Wilker CE, Jolete J, Smith SY, et al. A no observable carcinogenic effect dose level identified in Fischer 344 rats following daily treatment with PTH (1-84) for 2 years: Role of the C terminal receptor. J Bone Miner Res 2004;19:S1-98
117. Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 2006;368:973-974 (Pubitemid 44353676)
118. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-1022 (Pubitemid 44175011)
119. Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherents to osteoporosis treatment in clinical practice. Osteoporosis Int 2006;17:914-921 (Pubitemid 43781506)
120. Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis Int 2006;17:1645-1652 (Pubitemid 44477625)
121. Arden NK, Earl S, Fisher DJ, et al. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporosis Int 2006;17:1626-1629 (Pubitemid 44477622)
122. Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006;166:1209-1217 (Pubitemid 43877630)
123. Lundkvist J, Johnell O, Cooper C, et al. Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporosis Int 2006;17:201-211 (Pubitemid 43053582)
124. Vestergaard P, Jorgensen NR, Mosekilde L, et al. Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk. A meta analysis. Osteoporosis Int 2007;18:45-47 (Pubitemid 44885495)